Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

dc.contributor.authorKoch, Michael O.
dc.contributor.authorCho, Jane S.
dc.contributor.authorKaimakliotis, Hristos Z.
dc.contributor.authorCheng, Liang
dc.contributor.authorSangale, Zaina
dc.contributor.authorBrawer, Michael
dc.contributor.authorWelbourn, William
dc.contributor.authorReid, Julia
dc.contributor.authorStone, Steven
dc.contributor.departmentDepartment of Urology, IU School of Medicineen_US
dc.date.accessioned2017-03-02T18:21:18Z
dc.date.available2017-03-02T18:21:18Z
dc.date.issued2016-07
dc.description.abstractBACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. OBJECTIVE: We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP. METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group. RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031). CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationKoch, M. O., Cho, J. S., Kaimakliotis, H. Z., Cheng, L., Sangale, Z., Brawer, M., ... & Stone, S. (2016). Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer Biomarkers, 17(1), 83-88.en_US
dc.identifier.urihttps://hdl.handle.net/1805/11993
dc.language.isoenen_US
dc.publisherIOSen_US
dc.relation.isversionof10.3233/CBM-160620en_US
dc.relation.journalCancer Biomarkersen_US
dc.rightsAttribution-NonCommercial 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/us
dc.sourcePublisheren_US
dc.subjectprostate canceren_US
dc.subjectprostatectomyen_US
dc.subjectcell cycle progression scoreen_US
dc.titleUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrenceen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Koch_2016_use.pdf
Size:
167.28 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: